With transformational change likely off the table, healthcare and pharmaceutical companies should be well-positioned to weather the next presidential term.
Democrats could sweep the November elections according to many independent polls and political experts. What would that mean for the healthcare and pharmaceutical sectors, which have shown sensitivity to the political landscape?
